How to Submit to Advances In Cancer Research Journal
Most people approach the journal with a completely wrong strategy. They see it listed on PubMed and assume the process is straightforward. It isn't, especially not if your paper deals with anything in the more niche subfields like liquid biopsy or tumor microenvironment profiling. I spent about three weeks preparing a manuscript for submission and another six waiting for the first editorial decision. The gap between what the guidelines say and what actually happens during review is where most rejections happen. Advances In Cancer Research Journal covers oncology across multiple domains — basic research, translational studies, clinical trials, and occasionally methodological advances. The journal gets a high volume of submissions, which means the initial desk rejection rate is not insignificant. Editors at this level filter heavily based on novelty claims and mechanistic depth. A paper that says "we found something new" without addressing how it changes existing models will get desk-rejected within days. I learned this the hard way with my own submission on immune checkpoint inhibitors. The editor's comment was essentially: "This reads like a validation study, not an advance." I had misread the scope entirely. Here's the part nobody tells you: the journal prefers work that has a clear translational angle even if it's basic science. Pure mechanistic papers without any discussion of clinical relevance tend to get routed to different journals or asked to be reframed before peer review begins. Your discussion section needs to explicitly address what this finding means for patient outcomes or therapeutic development.
The Submission Process
The submission portal is standard — you upload your manuscript, figures, and supplementary materials as separate files. But the file requirements are where people stumble. The journal wants figures as separate TIFF or EPS files at a minimum of 300 DPI. Text files go as Word documents. They do not accept PDFs for the main manuscript body. If you've been formatting everything as a single PDF for convenience, you'll get an administrative return before it ever reaches an editor. I've seen this happen to senior investigators who assumed the system would accept what they sent. Cover letters matter more here than in many other oncology journals. The editor is looking for a one-paragraph summary that states: what gap exists, what you did, and why it advances the field. Don't rehash the abstract. They have the abstract. They want to know why your paper belongs in this specific journal versus Nature Cancer or Cancer Research. Spend twenty minutes on the cover letter. It's the first thing they read.
Peer Review Realities
Review times typically range from six to ten weeks for the first decision. I've seen it take as little as four weeks on fast-track cases and as long as fourteen when reviewers request additional experiments. The journal uses single-blind review, meaning reviewers know your identity but you don't know theirs. This sometimes leads to overly cautious reviewers who demand controls you already included in your supplementary data. When this happens, your response letter is critical. Cite the exact figure panels and pages where you already addressed their concern rather than apologizing and adding more data you don't have. One thing that catches people off guard: the journal frequently asks for original, unprocessed western blot images and raw sequencing data files at the revision stage. Not all at submission, but during revisions. Keep your raw data organized from day one. I lost about two days because my sequencing FASTQ files were scattered across three different servers. Had to reconstruct the directory and verify MD5 checksums before resubmitting.
Get the Full Details
Common Pitfalls
Statistical reporting is the number one reason for revision requests. Many authors list p-values without stating which test was used, how many comparisons were made, or whether corrections for multiple testing were applied. If your study involves twelve different treatment groups, a simple t-test everywhere will get flagged. Use the appropriate method — Bonferroni, Benjamini-Hochberg, or whatever your field standard is — and state it clearly in the methods section. References are often overlooked. The journal expects recent citations alongside foundational work. If your reference list is 80% papers from before 2018, reviewers will question whether you're actually current with the field. Conversely, if you cite only the last two years, it looks like you're chasing trends rather than building on established knowledge. Aim for a mix, and make sure at least some of your citations are from this journal itself. Editors notice when your bibliography skips their publication list entirely.
Acceptance and Beyond
Once accepted, you'll receive proofs within about two weeks. This is your last chance to catch errors. I once saw a coauthor's name misspelled in the galley proof that hadn't appeared in any earlier version. Catching it at that stage was relatively easy. Missing it meant a correction notice later, which stays attached to the record permanently. Open access options are available through the standard APC route. If your institution has a read-and-publish agreement, check with your library first — you might not need to pay out of pocket. The APC is on the higher end compared to some society journals, so budget accordingly if funding is a constraint. The journal itself is a solid venue for oncology research with decent visibility in the PubMed index. It's not Nature or Cell, and no one should treat it as a prestige play. But for specialized work that fits their scope — particularly mechanistic studies with clear biological relevance — it's a reasonable target. Just make sure your paper actually advances something rather than confirming what's already known.
